Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

zydus lifesciences limited - temozolomide (unii: yf1k15m17y) (temozolomide - unii:yf1k15m17y) - temozolomide 5 mg - temozolomide capsules are indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment. temozolomide capsules are indicated for the treatment of adult patients with refractory anaplastic astrocytoma, i.e. patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine. temozolomide is contraindicated in patients who have a history of hypersensitivity reaction (such as urticaria, allergic reaction including anaphylaxis, toxic epidermal necrolysis, and stevens-johnson syndrome) to any of its components. temozolomide is also contraindicated in patients who have a history of hypersensitivity to dacarbazine (dtic), since both drugs are metabolized to 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide (mtic). pregnancy category d. see warnings and precautions section. temozolomide can cause fetal harm when administered to a pregnant woman. five consecutive days of oral temozolomi

Kanada - engleski - Health Canada

taro pharmaceuticals inc - temozolomide - capsule - 5mg - temozolomide 5mg - antineoplastic agents

Kanada - engleski - Health Canada

taro pharmaceuticals inc - temozolomide - capsule - 20mg - temozolomide 20mg - antineoplastic agents

Kanada - engleski - Health Canada

taro pharmaceuticals inc - temozolomide - capsule - 140mg - temozolomide 140mg - antineoplastic agents

Kanada - engleski - Health Canada

taro pharmaceuticals inc - temozolomide - capsule - 250mg - temozolomide 250mg - antineoplastic agents

Kanada - engleski - Health Canada

taro pharmaceuticals inc - temozolomide - capsule - 180mg - temozolomide 180mg - antineoplastic agents

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

merck sharp & dohme llc - temozolomide (unii: yf1k15m17y) (temozolomide - unii:yf1k15m17y) - temozolomide 5 mg - temodar is indicated for the treatment of adults with newly diagnosed glioblastoma, concomitantly with radiotherapy and then as maintenance treatment. temodar is indicated for the: - adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma; - treatment of adults with refractory anaplastic astrocytoma. temodar is contraindicated in patients with a history of serious hypersensitivity reactions to: - temozolomide or any other ingredients in temodar; and - dacarbazine, since both temozolomide and dacarbazine are metabolized to the same active metabolite 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide. reactions to temodar have included anaphylaxis [see adverse reactions (6.2)]. risk summary based on findings from animal studies and its mechanism of action [see clinical pharmacology (12.1)] , temodar can cause fetal harm when administered to a pregnant woman. available postmarketing reports describe cases of spontaneous abortions and congenital malformations, including polymalformations with cen

Kanada - engleski - Health Canada

apotex inc - temozolomide - capsule - 5mg - temozolomide 5mg - antineoplastic agents

Kanada - engleski - Health Canada

apotex inc - temozolomide - capsule - 20mg - temozolomide 20mg - antineoplastic agents

Kanada - engleski - Health Canada

apotex inc - temozolomide - capsule - 140mg - temozolomide 140mg - antineoplastic agents